Pharmaceuticals

Next Generation Drug Conjugates Market Revenue Projected To Hit $23.73 Billion By 2030 With 18.1% CAGR

May 1, 2026May 1, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Forecasted Market Size Trajectory Of The Next Generation Drug Conjugates Market From 2026 To 2030?

The next generation drug conjugates market has witnessed significant growth in its size over recent years. It is projected to expand from $2.47 billion in 2025 to $2.85 billion in 2026, achieving a compound annual growth rate (CAGR) of 15.5%. This historical growth can be ascribed to several factors, including the limitations inherent in conventional chemotherapy, notable advancements in biologics research, a rise in cancer prevalence, the emergence and expansion of specialty pharma companies, and the proven clinical success of early drug conjugates.

The next generation drug conjugates market size is anticipated to experience swift expansion over the coming years. This market is projected to reach $5.1 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 15.7%. Factors contributing to this growth during the forecast period include the broadening scope of personalized medicine, expanding oncology drug pipelines, advancements in linker and payload chemistry, increased investments in research and development, and a rise in regulatory approvals. Key trends anticipated during this period encompass the increased uptake of targeted drug delivery systems, a heightened emphasis on precision oncology treatments, the development of advanced payload technologies, more widespread clinical application of conjugated therapeutics, and a greater need for drugs that are both safer and highly effective.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19124&type=smp

What Significant Factors Are Influencing The Next Generation Drug Conjugates Market Expansion?

An increasing prevalence of cancer is anticipated to fuel the expansion of the next-generation drug conjugates market in the future. Cancer encompasses a range of diseases characterized by the unrestrained multiplication and dissemination of abnormal cells within the body. The escalation in cancer cases is primarily attributed to factors such as an aging population, lifestyle choices, environmental exposures, advancements in detection, genetic predispositions, and infectious agents. Next-generation drug conjugates contribute to alleviating cancer by delivering precise therapies directly to malignant cells, thereby boosting treatment effectiveness while minimizing injury to healthy tissues. For instance, in February 2025, as per Cancer Australia, an Australia-based government agency, 4,641 new pancreatic cancer cases were reported in 2024, with 2,414 affecting males and 2,227 females, indicating an increase from 3,968 cases in 2023. Hence, the rising incidence of cancer is a key driver for the growth of the next-generation drug conjugates market.

What Are The Main Segments Within The Next Generation Drug Conjugates Market Segment Structure?

The next generation drug conjugates market covered in this report is segmented –

1) By Next-Generation Drug Conjugates Type: Peptide Receptor Radionuclide Therapy, Ligand Mediated RNAI Conjugate, Ligand Conjugated Anti Sense Medicine, Peptide Drug Conjugate

2) By Targeting Ligand Type: Amino Sugar, Lipid, Peptide, Small Molecule, Virus-Like Particles

3) By Payload Type: Oligonucleotide, Radionuclide, Peptide, Small Molecule

4) By Therapy: Monotherapy, Combination Therapy

5) By Indication: Gastroenteropancreatic Neuroendocrine Tumors, Prostate Cancer, Leptomeningeal Carcinomatosis Caused By Breast Cancer Brain Metastases, Hereditary Transthyretin Amyloidosis, Atherosclerotic Cardiovascular Diseases, Severe Hypertriglyceridemia, Hereditary Angioedema, Acute Hepatic Porphyria, Other Indications

Subsegments:

1) By Peptide Receptor Radionuclide Therapy (PRRT): Somatostatin Analogues, Radiolabeled Peptides

2) By Ligand Mediated RNAi Conjugate: SiRNA Ligand Conjugates, ShRNA Ligand Conjugates

3) By Ligand Conjugated Anti-Sense Medicine: Oligonucleotide Ligand Conjugates, Antisense Oligonucleotide Ligand Conjugates

4) By Peptide Drug Conjugate: Cytotoxic Peptide Conjugates, Therapeutic Peptide Conjugates

Which Trends Are Impacting The Progress Of The Next Generation Drug Conjugates Market?

Major companies operating in the next-generation drug conjugates market are increasingly utilizing strategic partnerships to bolster their research and development capabilities, expedite product innovation, and grow their market presence. Strategic partnerships represent a collaborative approach where companies leverage each other’s strengths and resources to attain mutual benefits and success. As an illustration, in November 2023, Prelude Therapeutics Incorporated, a US-based clinical-stage precision oncology company, collaborated with AbCellera Biologics Inc., a Canada-based biotechnology company, to develop first-in-class precision antibody-drug conjugates (ADCs) for oncology. This alliance will concentrate on the discovery, development, and commercialization of innovative antibody-drug conjugates (ADCs), beginning with a program that targets a SMARCA degrader linked to a novel antibody. This strategy seeks to broaden the therapeutic applications of Prelude’s small-molecule SMARCA2 selective degraders to a wider patient population, especially those with cancers unrelated to SMARCA4 mutations.

Who Are The Companies Participating In The Next Generation Drug Conjugates Market?

Major companies operating in the next generation drug conjugates market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Novartis International AG, AstraZeneca PLC, Daiichi Sankyo Company Limited, Eisai Co Ltd., Bicycle Therapeutics plc, Zymeworks Inc., Genentech Inc., MacroGenics Inc., Abzena plc, Innate Pharma S.A., CytomX Therapeutics Inc., ImmunoGen Inc., Ascentage Pharma Group International, Mersana Therapeutics Inc., Antengene Corporation Limited, Nurix Therapeutics Inc., Tubulis GmbH

Get The Full Next Generation Drug Conjugates Market Report:

https://www.thebusinessresearchcompany.com/report/next-generation-drug-conjugates-global-market-report

Which Region Leads The Next Generation Drug Conjugates Market In Terms Of Market Share?

North America was the largest region in the next generation drug conjugates market in 2025. The regions covered in the next generation drug conjugates market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Next Generation Drug Conjugates Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/next-generation-drug-conjugates-global-market-report

Browse Through More Reports Similar to the Global Next Generation Drug Conjugates Market 2026, By The Business Research Company

Antibody Drug Conjugates Market Report 2026

https://www.thebusinessresearchcompany.com/report/antibody-drug-conjugates-global-market-report

Conjugate Vaccine Market Report 2026

https://www.thebusinessresearchcompany.com/report/conjugate-vaccine-global-market-report

Bladder Cancer Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/bladder-cancer-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795